Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pay-For-Delay Deals May Be Smaller After Supreme Court Okays FTC Suits

Executive Summary

Justices rule FTC can make its case in court that Solvay’s reverse payment settlement with Actavis and two other generic companies was anticompetitive; GPhA says opinion could decrease the number of patent challenges by generic manufacturers, but Actavis pledges to continue defending these deals.

You may also be interested in...



FTC v. Endo: Exclusive Licenses, ‘Supracompetitive Prices’ Are Protected By Patent Laws

In an unsealed redacted opinion dismissing FTC’s complaint, district judge says Endo’s agreement with Impax, which left it the sole marketer of oxymorphone ER, falls within the bounds of anticompetitive activity protected by patent laws.

FTC v. Endo: Exclusive Licenses, ‘Supracompetitive Prices’ Are Protected By Patent Laws

In an unsealed redacted opinion dismissing FTC’s complaint, district judge says Endo’s agreement with Impax, which left it the sole marketer of oxymorphone ER, falls within the bounds of anticompetitive activity protected by patent laws.

FTC Claims Revived Over Teva-AbbVie 'Pay For Delay' Deal

AbbVie and FTC both see wins and setbacks in Third Circuit ruling on case involving reverse-payment patent settlement with Teva.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055436

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel